BPI Interviews Purification And Pharma Analytics Leader

This video explores Thermo Fisher Scientific’s pivotal role in accelerating the development and commercialization of life-saving therapeutics and vaccines, particularly in response to the global pandemic. Highlighting dramatic reductions in development timelines — from a decade to just months — Jean Luo, VP, Purification and Pharma Analytics, emphasizes the company's commitment to enabling customer success through innovative purification solutions and cutting-edge technologies.

Using key examples, Luo highlights Thermo Fisher Scientific’s multifaceted approach to supporting the evolving needs of advanced therapies, with innovations spanning both product development and operational strategy. Complementing these product innovations are strategic investments in supply chain resilience, which have led to significantly reduced lead times for essential materials such as ion exchange resins — helping customers maintain continuity in development and manufacturing.

The discussion also explores the growing use of digital PCR, valued for its high sensitivity and precision in nucleic acid quantification, especially in low-copy applications central to cell and gene therapy workflows. Together, these advancements reflect Thermo Fisher’s commitment to delivering end-to-end workflow solutions — from sample preparation to software integration — that simplify operations, accelerate development timelines, and ultimately enable faster delivery of life-saving treatments to patients.